CSIMarket



Worst Performing Stocks In Healthcare Sector 2024 Year To Date



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares increased by 3.89% on average, in Healthcare Sector 2024 year to date.

Here are the Worst performing stocks in Healthcare Sector.




SBFM

$0.3929

$-27.0371 -98.57%
2024 Year to Date


SBFM

$0.3929

$-27.0371 -98.57%



Sunshine Biopharma Inc

Sunshine Biopharma Inc stock declined -98.57% 2024 year to date.


Sunshine Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other diseases. They utilize their expertise in drug discovery and development to create innovative treatments that target specific molecular targets in order to deliver more effective and personalized therapies for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.003 mill. $ 26.740 mill. $ -4.087 mill. 0 mill. - Y/Y 54.09 %
Market Cap. Revenues TTM Net Income TTM

$ 0.003 mill.


$ 26.740 mill.


$ -4.087 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 54.09 %


MRQ Y/Y - %



PBLA

$0.4

$-17.5340 -97.77%
2024 Year to Date


PBLA

$0.4

$-17.5340 -97.77%



Panbela Therapeutics Inc

Panbela Therapeutics Inc stock dropped -97.77% 2024 year to date.


Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.250 mill. $ - mill. $ -27.270 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.250 mill.


$ - mill.


$ -27.270 mill.

Employees Shares Outstanding P/E

-


3 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ALLR

$0.4678

$-10.3942 -95.69%
2024 Year to Date


ALLR

$0.4678

$-10.3942 -95.69%



Allarity Therapeutics Inc

Allarity Therapeutics Inc shares declined -95.69% 2024 year to date.


Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.058 mill. $ - mill. $ -20.698 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.058 mill.


$ - mill.


$ -20.698 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BTTX

$0.0081

$-0.1746 -95.57%
2024 Year to Date


BTTX

$0.0081

$-0.1746 -95.57%



Better Therapeutics Inc

Better Therapeutics Inc shares dropped -95.57% 2024 year to date.


Better Therapeutics Inc is a digital therapeutics company that combines evidenced-based clinical interventions with software technology to address chronic diseases. Their business model revolves around developing and delivering prescription software applications to patients, which are meant to be used alongside pharmaceutical therapies. Their aim is to provide personalized and scalable solutions that have the potential to improve health outcomes and reduce healthcare costs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.312 mill. $ - mill. $ -31.573 mill. 39 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.312 mill.


$ - mill.


$ -31.573 mill.

Employees Shares Outstanding P/E

-


39 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



INBS

$2.16

$-45.3312 -95.45%
2024 Year to Date


INBS

$2.16

$-45.3312 -95.45%



Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc shares declined -95.45% 2024 year to date.


Intelligent Bio Solutions Inc*s business model focuses on providing intelligent solutions in the bio industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.493 mill. $ 2.516 mill. $ -10.067 mill. 2 mill. - Y/Y 80.24 %
Market Cap. Revenues TTM Net Income TTM

$ 4.493 mill.


$ 2.516 mill.


$ -10.067 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 80.24 %


MRQ Y/Y - %



MOTS

$0.0694

$-1.2290 -94.65%
2024 Year to Date


MOTS

$0.0694

$-1.2290 -94.65%



Motus Gi Holdings Inc

Motus Gi Holdings Inc stock went down -94.65% 2024 year to date.


Motus Gi Holdings Inc operates as a medical technology company that designs, develops, and commercializes innovative solutions for gastrointestinal endoscopy procedures. Their business model is centered around providing healthcare professionals with advanced imaging and therapeutic technologies to improve patient outcomes and enhance procedural efficiency.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.598 mill. $ -441.767 mill. $ -1.891 mill. 9 mill. - Y/Y -41.28 %
Market Cap. Revenues TTM Net Income TTM

$ 0.598 mill.


$ -441.767 mill.


$ -1.891 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -41.28 %


MRQ Y/Y - %



LYRA

$0.3101

$-4.8899 -94.04%
2024 Year to Date


LYRA

$0.3101

$-4.8899 -94.04%



Lyra Therapeutics Inc

Lyra Therapeutics Inc stock dropped -94.04% 2024 year to date.


Lyra Therapeutics Inc is a biotechnology company that focuses on developing drug-delivery systems for patients with ear, nose, and throat (ENT) diseases. They utilize their proprietary technology, known as XTreo, to precisely deliver therapeutics to targeted areas within the ENT region. Their business model revolves around developing and commercializing these unique drug-delivery solutions to address unmet medical needs in the ENT field.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 17.661 mill. $ 1.423 mill. $ -61.759 mill. 57 mill. - Y/Y 51.53 %
Market Cap. Revenues TTM Net Income TTM

$ 17.661 mill.


$ 1.423 mill.


$ -61.759 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 51.53 %


MRQ Y/Y - %



CNSP

$3.62

$-55.8800 -93.92%
2024 Year to Date


CNSP

$3.62

$-55.8800 -93.92%



Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc shares declined -93.92% 2024 year to date.


CNS Pharmaceuticals Inc*s business model focuses on developing innovative solutions and treatments for central nervous system diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 31.540 mill. $ 0.034 mill. $ -17.464 mill. 9 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 31.540 mill.


$ 0.034 mill.


$ -17.464 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SINT

$4.73

$-72.6700 -93.89%
2024 Year to Date


SINT

$4.73

$-72.6700 -93.89%



Sintx Technologies Inc

Sintx Technologies Inc shares dropped -93.89% 2024 year to date.


Sintx Technologies Inc is a company that operates under a business model focused on developing and commercializing silicon nitride-based ceramics for various applications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 163.000 mill. $ 2.775 mill. $ -8.852 mill. 34 mill. - Y/Y 27.46 %
Market Cap. Revenues TTM Net Income TTM

$ 163.000 mill.


$ 2.775 mill.


$ -8.852 mill.

Employees Shares Outstanding P/E

-


34 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 27.46 %


MRQ Y/Y - %



AMPE

$0.13

$-1.9500 -93.75%
2024 Year to Date


AMPE

$0.13

$-1.9500 -93.75%



Ampio Pharmaceuticals inc

Ampio Pharmaceuticals Inc shares dropped -93.75% 2024 year to date.


Ampio Pharmaceuticals Inc is a biopharmaceutical company primarily focused on the development of therapies for debilitating diseases. Their business model revolves around identifying unmet medical needs and developing innovative drug candidates to address these needs. They aim to create value through successful clinical development and commercialization of their products, ultimately benefiting patients and generating revenue for the company.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.105 mill. $ - mill. $ -8.632 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.105 mill.


$ - mill.


$ -8.632 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



NDRA

$0.101

$-1.4890 -93.65%
2024 Year to Date


NDRA

$0.101

$-1.4890 -93.65%



Endra Life Sciences Inc

Endra Life Sciences Inc stock dropped -93.65% 2024 year to date.


Endra Life Sciences Inc*s business model focuses on developing and commercializing advanced imaging technologies and solutions for medical and industrial applications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.091 mill. $ - mill. $ -9.893 mill. 11 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.091 mill.


$ - mill.


$ -9.893 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ACON

$0.2922

$-3.0262 -91.19%
2024 Year to Date


ACON

$0.2922

$-3.0262 -91.19%



Aclarion Inc

Aclarion Inc shares went down -91.19% 2024 year to date.


Aclarion Inc is a technology company that operates on a software-as-a-service (SaaS) business model. They provide their customers with cloud-based solutions, enabling them to streamline and automate their business processes efficiently. Aclarion offers a range of customizable software solutions, including data management, project management, and collaboration tools, tailored to meet the specific needs of their clients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.590 mill. $ 0.060 mill. $ -6.127 mill. 5 mill. - Y/Y -60.29 %
Market Cap. Revenues TTM Net Income TTM

$ 1.590 mill.


$ 0.060 mill.


$ -6.127 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -60.29 %


MRQ Y/Y - %



GLYC

$0.2705

$-2.4495 -90.06%
2024 Year to Date


GLYC

$0.2705

$-2.4495 -90.06%



Glycomimetics Inc

Glycomimetics Inc stock declined -90.06% 2024 year to date.


Glycomimetics Inc is a biopharmaceutical company that utilizes its expertise in carbohydrate chemistry to develop novel drug candidates. Their business model involves researching and developing proprietary glycomimetic compounds that can target specific disease pathways. They then collaborate with pharmaceutical partners to further develop and commercialize these potential therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 17.436 mill. $ - mill. $ 0.000 mill. 64 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 17.436 mill.


$ - mill.


$ 0.000 mill.

Employees Shares Outstanding P/E

-


64 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



APVO

$0.781

$-7.0510 -90.03%
2024 Year to Date


APVO

$0.781

$-7.0510 -90.03%



Aptevo Therapeutics Inc

Aptevo Therapeutics Inc shares went down -90.03% 2024 year to date.


Aptevo Therapeutics Inc operates as a biotechnology company that focuses on the development of novel oncology and hematology therapeutics. The company primarily generates revenue through the sale of its products and potential collaborations with other pharmaceutical companies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.223 mill. $ - mill. $ -16.151 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.223 mill.


$ - mill.


$ -16.151 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ANTX

$1.99

$-17.8800 -89.98%
2024 Year to Date


ANTX

$1.99

$-17.8800 -89.98%



An2 Therapeutics Inc

An2 Therapeutics Inc stock went down -89.98% 2024 year to date.


An2 Therapeutics Inc is a biotechnology company that develops therapeutics for the treatment of rare diseases. Their business model focuses on research and development of innovative drugs that target specific genetic mutations responsible for these rare conditions, aiming to provide effective and personalized treatments. By collaborating with pharmaceutical partners and leveraging their expertise in drug discovery, An2 Therapeutics Inc aims to bring their therapies to market and improve the lives of patients with rare diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 51.034 mill. $ - mill. $ -59.676 mill. 26 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 51.034 mill.


$ - mill.


$ -59.676 mill.

Employees Shares Outstanding P/E

-


26 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MBIO

$0.1354

$-1.1846 -89.74%
2024 Year to Date


MBIO

$0.1354

$-1.1846 -89.74%



Mustang Bio inc

Mustang Bio Inc stock declined -89.74% 2024 year to date.


Mustang Bio Inc operates on a business model focused on developing advanced therapies for challenging diseases. They primarily engage in research, development, and commercialization of innovative gene and cell therapies. Mustang Bio Inc aims to provide cutting-edge treatments to patients in need by leveraging its expertise in gene editing technologies and strategic partnerships.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.106 mill. $ - mill. $ -70.209 mill. 8 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.106 mill.


$ - mill.


$ -70.209 mill.

Employees Shares Outstanding P/E

330


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CING

$0.6929

$-6.0271 -89.69%
2024 Year to Date


CING

$0.6929

$-6.0271 -89.69%



Cingulate Inc

Cingulate Inc stock went down -89.69% 2024 year to date.


Cingulate Inc operates as a software development company, specializing in delivering innovative solutions for various industries. With a focus on cutting-edge technologies, they provide customized software products and services to meet the specific needs of their clients. Their business model revolves around developing and implementing software solutions that optimize processes and enhance efficiency within organizations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.627 mill. $ - mill. $ -23.535 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.627 mill.


$ - mill.


$ -23.535 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



EFTR

$1.37

$-10.8800 -88.82%
2024 Year to Date


EFTR

$1.37

$-10.8800 -88.82%



Effector Therapeutics Inc

Effector Therapeutics Inc stock dropped -88.82% 2024 year to date.


Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.385 mill. $ - mill. $ -35.941 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3.385 mill.


$ - mill.


$ -35.941 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AMLX

$1.68

$-13.2900 -88.78%
2024 Year to Date


AMLX

$1.68

$-13.2900 -88.78%



Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc shares went down -88.78% 2024 year to date.


Amylyx Pharmaceuticals Inc*s business model revolves around researching, developing, and commercializing potential therapies for neurodegenerative diseases. They aim to identify promising drug candidates, conduct preclinical and clinical trials, and ultimately gain regulatory approval to market and sell their products. By focusing on innovative treatments, Amylyx Pharmaceuticals Inc aims to address unmet medical needs in the field of neurodegenerative disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 117.178 mill. $ 294.222 mill. $ 1.836 mill. 70 mill. - Y/Y 29,666.09 %
Market Cap. Revenues TTM Net Income TTM

$ 117.178 mill.


$ 294.222 mill.


$ 1.836 mill.

Employees Shares Outstanding P/E

80


70 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 29,666.09 %


MRQ Y/Y - %



VAXX

$0.1

$-0.7447 -88.16%
2024 Year to Date


VAXX

$0.1

$-0.7447 -88.16%



Vaxxinity Inc

Vaxxinity Inc shares dropped -88.16% 2024 year to date.


Vaxxinity Inc is a company that operates on a business model that focuses on the development and distribution of vaccines.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 12.652 mill. $ - mill. $ -56.934 mill. 127 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 12.652 mill.


$ - mill.


$ -56.934 mill.

Employees Shares Outstanding P/E

-


127 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HSDT

$1.06

$-7.0280 -86.89%
2024 Year to Date


HSDT

$1.06

$-7.0280 -86.89%



Helius Medical Technologies inc

Helius Medical Technologies Inc stock dropped -86.89% 2024 year to date.


Helius Medical Technologies Inc is a company that operates on a subscription-based business model, providing medical technology solutions for the treatment of neurological symptoms and conditions through its proprietary platform known as PoNS. This includes offering PoNS devices and related therapy services to healthcare providers and patients, with an aim to improve patient outcomes and quality of life.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.866 mill. $ 0.668 mill. $ -8.872 mill. 1 mill. - Y/Y 21.62 %
Market Cap. Revenues TTM Net Income TTM

$ 0.866 mill.


$ 0.668 mill.


$ -8.872 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 21.62 %


MRQ Y/Y - %



BIOL

$0.1452

$-0.9548 -86.80%
2024 Year to Date


BIOL

$0.1452

$-0.9548 -86.80%



Biolase Inc

Biolase Inc stock went down -86.80% 2024 year to date.


Biolase Inc*s business model revolves around developing and manufacturing dental laser systems and related products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.171 mill. $ 49.382 mill. $ -25.166 mill. 1 mill. - Y/Y -10.52 %
Market Cap. Revenues TTM Net Income TTM

$ 0.171 mill.


$ 49.382 mill.


$ -25.166 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -10.52 %


MRQ Y/Y - %



PRTG

$0.2542

$-1.6358 -86.55%
2024 Year to Date


PRTG

$0.2542

$-1.6358 -86.55%



Portage Biotech Inc.

Portage Biotech Inc. shares declined -86.55% 2024 year to date.


Portage Biotech Inc.*s business model involves the identification and development of innovative therapeutics and healthcare solutions, leveraging a unique portfolio of biotechnology companies and their technologies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.324 mill. $ - mill. $ -19.169 mill. 13 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3.324 mill.


$ - mill.


$ -19.169 mill.

Employees Shares Outstanding P/E

-


13 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



KA

$0.47

$-2.9300 -86.18%
2024 Year to Date


KA

$0.47

$-2.9300 -86.18%



Kineta Inc

Kineta Inc stock dropped -86.18% 2024 year to date.


Kineta Inc*s business model focuses on developing innovative therapeutics for various diseases, leveraging their expertise in immunology and drug discovery.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.517 mill. $ - mill. $ -74.869 mill. 12 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5.517 mill.


$ - mill.


$ -74.869 mill.

Employees Shares Outstanding P/E

-


12 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AZTR

$0.1452

$-0.9048 -86.17%
2024 Year to Date


AZTR

$0.1452

$-0.9048 -86.17%



Azitra Inc

Azitra Inc shares declined -86.17% 2024 year to date.


Azitra Inc is a company that operates on a business model focused on developing and commercializing microbiome-based therapeutics for various skin conditions. It aims to use the potential of the human skin microbiome to develop innovative and effective treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.930 mill. $ - mill. $ -14.217 mill. 20 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2.930 mill.


$ - mill.


$ -14.217 mill.

Employees Shares Outstanding P/E

-


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MRNS

$1.46

$-8.9400 -85.96%
2024 Year to Date


MRNS

$1.46

$-8.9400 -85.96%



Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc shares went down -85.96% 2024 year to date.


Marinus Pharmaceuticals Inc operates on a business model centered around developing and commercializing innovative therapeutics for rare neurological disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 83.004 mill. $ 31.478 mill. $ -138.305 mill. 57 mill. - Y/Y 7.22 %
Market Cap. Revenues TTM Net Income TTM

$ 83.004 mill.


$ 31.478 mill.


$ -138.305 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 7.22 %


MRQ Y/Y - %



RAPT

$3.48

$-20.8100 -85.67%
2024 Year to Date


RAPT

$3.48

$-20.8100 -85.67%



Rapt Therapeutics Inc

Rapt Therapeutics Inc shares declined -85.67% 2024 year to date.


Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 133.486 mill. $ - mill. $ -108.873 mill. 38 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 133.486 mill.


$ - mill.


$ -108.873 mill.

Employees Shares Outstanding P/E

41


38 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



REVB

$2.26

$-13.0400 -85.23%
2024 Year to Date


REVB

$2.26

$-13.0400 -85.23%



Revelation Biosciences Inc

Revelation Biosciences Inc stock declined -85.23% 2024 year to date.


Revelation Biosciences Inc*s business model focuses on developing innovative therapies and technologies for various medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.474 mill. $ - mill. $ 0.875 mill. 0 mill. 0.06 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.474 mill.


$ - mill.


$ 0.875 mill.

Employees Shares Outstanding P/E

-


0 mill.


0.06

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



QNRX

$0.72

$-4.1150 -85.11%
2024 Year to Date


QNRX

$0.72

$-4.1150 -85.11%



Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd shares went down -85.11% 2024 year to date.


Quoin Pharmaceuticals Ltd operates on a direct-to-consumer (DTC) business model by developing and manufacturing pharmaceutical products for individual customers. The company focuses on creating specialized medicines tailored to meet the unique healthcare needs of patients. Quoin Pharmaceuticals aims to establish a close relationship with consumers, providing high-quality and personalized medications while bypassing traditional intermediaries in the pharmaceutical industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.514 mill. $ 0.030 mill. $ -13.121 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.514 mill.


$ 0.030 mill.


$ -13.121 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CLDI

$0.22

$-1.2200 -84.72%
2024 Year to Date


CLDI

$0.22

$-1.2200 -84.72%



Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc stock dropped -84.72% 2024 year to date.


Calidi Biotherapeutics Inc*s business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 7.821 mill. $ - mill. $ -34.216 mill. 36 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 7.821 mill.


$ - mill.


$ -34.216 mill.

Employees Shares Outstanding P/E

-


36 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



TENX

$3.2

$-17.5920 -84.61%
2024 Year to Date


TENX

$3.2

$-17.5920 -84.61%



Tenax Therapeutics Inc

Tenax Therapeutics Inc shares went down -84.61% 2024 year to date.


Tenax Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing products for critical care patients with cardiovascular and pulmonary diseases. Their business model revolves around conducting research and clinical trials to bring innovative therapies to market. They generate revenue primarily by licensing their products to other pharmaceutical companies or through direct sales to hospitals and healthcare providers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.901 mill. $ - mill. $ 10.103 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3.901 mill.


$ - mill.


$ 10.103 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 170.04 %



GNLX

$2.38

$-12.4700 -83.97%
2024 Year to Date


GNLX

$2.38

$-12.4700 -83.97%



Genelux Corporation

Genelux Corporation stock declined -83.97% 2024 year to date.


Genelux Corporation*s business model revolves around the development and commercialization of innovative genetic-based therapies and technologies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 58.058 mill. $ - mill. $ -28.297 mill. 24 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 58.058 mill.


$ - mill.


$ -28.297 mill.

Employees Shares Outstanding P/E

-


24 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RNAZ

$1.18

$-5.2760 -81.72%
2024 Year to Date


RNAZ

$1.18

$-5.2760 -81.72%



Transcode Therapeutics Inc

Transcode Therapeutics Inc stock went down -81.72% 2024 year to date.


Transcode Therapeutics Inc*s business model revolves around developing innovative RNA-based therapies to treat a wide range of diseases. By leveraging their expertise in mRNA biology and proprietary drug delivery technology, they aim to create transformative treatments with optimized safety and efficacy profiles.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.068 mill. $ - mill. $ -17.056 mill. 5 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6.068 mill.


$ - mill.


$ -17.056 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AEON

$1.36

$-6.0700 -81.70%
2024 Year to Date


AEON

$1.36

$-6.0700 -81.70%



Aeon Biopharma inc

Aeon Biopharma Inc stock went down -81.70% 2024 year to date.


Aeon Biopharma Inc.*s business model focuses on the development and commercialization of biopharmaceutical products, emphasizing innovation and collaboration for the advancement of healthcare.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 83.466 mill. $ - mill. $ 4.825 mill. 61 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 83.466 mill.


$ - mill.


$ 4.825 mill.

Employees Shares Outstanding P/E

-


61 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 451.84 %



SPRC

$0.9323

$-4.1577 -81.68%
2024 Year to Date


SPRC

$0.9323

$-4.1577 -81.68%



Scisparc Ltd

Scisparc Ltd stock dropped -81.68% 2024 year to date.


Scisparc Ltd operates through a specific business model that focuses on providing innovative technological solutions in a particular industry or market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.331 mill. $ 2.879 mill. $ 5.883 mill. 0 mill. 0.06 Y/Y 113.73 %
Market Cap. Revenues TTM Net Income TTM

$ 0.331 mill.


$ 2.879 mill.


$ 5.883 mill.

Employees Shares Outstanding P/E

-


0 mill.


0.06

Revenue Growth Income Growth

MRQ Y/Y 113.73 %


MRQ Y/Y 126.97 %



DMTK

$0.317

$-1.3430 -80.90%
2024 Year to Date


DMTK

$0.317

$-1.3430 -80.90%



Dermtech Inc

Dermtech Inc stock went down -80.90% 2024 year to date.


Dermtech Inc is a biotechnology company that specializes in non-invasive diagnostic tests for skin cancer and other skin conditions. Their business model revolves around developing and commercializing their proprietary technology, which allows for the accurate and early detection of skin cancer through a simple adhesive patch. By providing dermatologists with a less invasive and more efficient diagnostic tool, Dermtech aims to improve patient outcomes and revolutionize the field of dermatology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11.002 mill. $ 13.370 mill. $ -101.807 mill. 35 mill. - Y/Y 24.01 %
Market Cap. Revenues TTM Net Income TTM

$ 11.002 mill.


$ 13.370 mill.


$ -101.807 mill.

Employees Shares Outstanding P/E

-


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 24.01 %


MRQ Y/Y - %



PACB

$1.85

$-7.7400 -80.71%
2024 Year to Date


PACB

$1.85

$-7.7400 -80.71%



Pacific Biosciences Of California Inc

Pacific Biosciences Of California Inc shares declined -80.71% 2024 year to date.


Pacific Biosciences of California Inc*s business model revolves around the development and commercialization of innovative sequencing systems that enable scientists and researchers to study the complexity of biology. They provide high-resolution genetic analysis solutions, offering a comprehensive platform that includes consumables, systems, and data analysis software to support genomic analysis.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 498.719 mill. $ 199.162 mill. $ -296.898 mill. 270 mill. - Y/Y -1.59 %
Market Cap. Revenues TTM Net Income TTM

$ 498.719 mill.


$ 199.162 mill.


$ -296.898 mill.

Employees Shares Outstanding P/E

500


270 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -1.59 %


MRQ Y/Y - %



CDIO

$0.5917

$-2.4683 -80.66%
2024 Year to Date


CDIO

$0.5917

$-2.4683 -80.66%



Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings Inc shares went down -80.66% 2024 year to date.


Cardio Diagnostics Holdings Inc is a medical diagnostics company that specializes in cardiovascular health. Their business model focuses on developing and commercializing innovative diagnostic solutions for detecting and monitoring heart-related conditions. By leveraging advanced technologies and partnerships, they aim to provide healthcare professionals with accurate and timely information to enhance their patients* cardiovascular care.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 5.338 mill. $ -11.508 mill. - mill. - Y/Y -99.72 %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 5.338 mill.


$ -11.508 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y -99.72 %


MRQ Y/Y - %



AGRX

$0.3581

$-1.4819 -80.54%
2024 Year to Date


AGRX

$0.3581

$-1.4819 -80.54%



Agile Therapeutics Inc

Agile Therapeutics Inc shares declined -80.54% 2024 year to date.


is a women's healthcare


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.659 mill. $ 19.838 mill. $ -7.791 mill. 5 mill. - Y/Y 32.07 %
Market Cap. Revenues TTM Net Income TTM

$ 1.659 mill.


$ 19.838 mill.


$ -7.791 mill.

Employees Shares Outstanding P/E

28


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 32.07 %


MRQ Y/Y - %



NLSP

$0.1162

$-0.4717 -80.23%
2024 Year to Date


NLSP

$0.1162

$-0.4717 -80.23%



Nls Pharmaceutics Ltd

Nls Pharmaceutics Ltd stock went down -80.23% 2024 year to date.


Nls Pharmaceutics Ltd is a pharmaceutical company with a business model centered around research, development, and commercialization of innovative drug therapies. They focus on designing and formulating novel drug delivery systems that improve the efficacy and safety of existing medications. Nls Pharmaceutics aims to bring their advanced drug delivery technologies to market by partnering with larger pharmaceutical companies or seeking regulatory approval for their own products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.436 mill. $ - mill. $ -12.172 mill. 38 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4.436 mill.


$ - mill.


$ -12.172 mill.

Employees Shares Outstanding P/E

-


38 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com